| Date Filed | Type | Description |
| 07/02/2021 |
REVOKED
| Form REVOKED - Commission order revoking Exchange Act registration [Section 12(j)]: |
| 10/15/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/10/2019 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 09/10/2019 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 04/01/2019 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 02/20/2019 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
| 02/07/2019 |
8-K
| Quarterly results |
| 01/03/2019 |
8-K
| Quarterly results |
| 12/03/2018 |
DEF 14C
| Form DEF 14C - Other definitive information statements: |
| 11/20/2018 |
PRE 14C
| Form PRE 14C - Other preliminary information statements: |
| 11/20/2018 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 11/15/2018 |
10-Q/A
| Quarterly Report for the period ended September 30, 2018 [amend] |
| 11/14/2018 |
10-Q
| Quarterly Report for the period ended September 30, 2018 |
| 11/09/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/01/2018 |
10-Q/A
| Quarterly Report for the period ended June 30, 2018 [amend] |
| 09/27/2018 |
10-Q
| Quarterly Report for the period ended June 30, 2018 |
| 09/27/2018 |
10-Q
| Quarterly Report for the period ended March 31, 2018 |
| 08/24/2018 |
8-K/A
| Financial Statements and Exhibits|
Docs:
|
"CONSENT",
"2. Summary of Critical Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America . Principles of Consolidation The consolidated financial statements include the accounts of CytoBioscience, Inc., and its wholly owned subsidiaries, Cytocentrics Bioscience GmbH, Cytocentrics B.V. and SolubleBioscience, Inc. . All intercompany balances have been eliminated in consolidation. Foreign Currency Translation For subsidiaries whose functional currencies are not the U.S. dollar, the Company uses the average exchange rate for the year and the exchange rate at the balance sheet date, to translate the operating results and financial position to U.S. dollar, the...",
"WestMountain Company and CytoBioscience, Inc. Pro-Forma Condensed Consolidated Balance Sheet For the year ended December 31, 2017 WestMountain CytoBioscience Adjustments Pro Forma Combined" |
|
| 05/23/2018 |
3
| Dean Alan H. (Director) has filed a Form 3 on WESTMOUNTAIN Co |
| 05/21/2018 |
3
| Knott Thomas (Chief Science Officer) has filed a Form 3 on WESTMOUNTAIN Co |
| 05/16/2018 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 05/15/2018 |
3
| HUI SHING LEONG (Director) has filed a Form 3 on WESTMOUNTAIN Co |
| 05/09/2018 |
3
| Castella Paul (Director) has filed a Form 3 on WESTMOUNTAIN Co |
| 05/02/2018 |
3
| Garvin James R. (CEO and President) has filed a Form 3 on WESTMOUNTAIN Co |
| 05/01/2018 |
4
| BOCO Investments LLC (10% Owner) has filed a Form 4 on WESTMOUNTAIN Co|
Txns:
| Acquired 200,944 shares
@ $0.75, valued at
$150.7k
Bought 801,438 shares
@ $0.75, valued at
$601.1k
Bought 1,002,382 warrants
@ $0.95, valued at
$952.3k
|
|
| 05/01/2018 |
4
| BOCO Investments LLC (10% Owner) has filed a Form 4 on WESTMOUNTAIN Co|
Txns:
| Acquired 200,944 shares
@ $0.75, valued at
$150.7k
Bought 801,438 shares
@ $0.75, valued at
$601.1k
Bought 1,002,382 warrants
@ $0.95, valued at
$952.3k
|
|
| 05/01/2018 |
SC 13D/A
| BOCO Investments LLC reports a 19% stake in WESTMOUNTAIN COMPANY |
| 05/01/2018 |
3
| Clements Ian William David (Director) has filed a Form 3 on WESTMOUNTAIN Co |
| 04/30/2018 |
3
| Bourg Henry C. (CFO) has filed a Form 3 on WESTMOUNTAIN Co |
| 04/30/2018 |
3
| Hui Sue Lynn (Director) has filed a Form 3 on WESTMOUNTAIN Co |
| 03/23/2018 |
SC 14F1
| Form SC 14F1 - Statement regarding change in majority of directors [Rule 14f-1]: |
| 03/23/2018 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Changes in Registrant's Certi...|
Docs:
|
"Agreement of Merger and Plan of Reorganization by and among the Registrant, WASM Acquisition Corp. and CytoBioscience, Inc",
"Lock-up Agreement between the Registrant and the officers, directors and shareholders party thereto",
"Securities Purchase Agreement between the Registrant and the investor parties thereto",
"Investment Banking Agreement between Registrant and Divine Capital",
"Letter from EKS&H LLLP to the Securities and Exchange Commission",
"San Antonio, TX – – March 23, 2018 – CytoBioscience, Inc. , a revenue-generating ion channel screening business providing medical instrumentation and research services to organizations in the pharmaceutical and drug research market, today announced that it has closed a merger with WestMountain Company , effective March 19, 2018. On March 19, 2018, WestMountain entered into a Merger Agreement with CytoBioscience, Inc., a Delaware corporation . As per the terms of the Merger Agreement, a subsidiary of WestMountain merged into CytoBioscience, with CytoBioscience surviving the merger and becoming a wholly-owned subsidiary of WestMountain, and the shareholders of CytoBioscience becoming shareholders of WestMountain. Pursuant to terms of the Merger Agreement, all outstanding shares of capital st..." |
|
| 03/15/2018 |
10-K
| Annual Report for the period ended December 31, 2017 |
| 01/16/2018 |
DEF 14C
| Form DEF 14C - Other definitive information statements: |
|